LARGE SCALE T CELL EPITOPE DISCOVERY - COVID Supplement

大规模 T 细胞表位发现 - COVID 补充品

• 批准号: 10612326
• 负责人: STEPHEN WILSON
• 金额: $ 80万
• 依托单位: LA JOLLA INSTITUTE FOR IMMUNOLOGY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2023-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10612326
• 关键词: 2019-nCoV; CD8-Positive T-Lymphocytes; CD8B1 gene; Cells; Contracts; Coronavirus; Dimethyl Sulfoxide; Epitopes; Freeze Drying; Ships; T cell response; T-Lymphocyte Epitopes; Testing; Toxic effect; coronavirus disease

The SARS-CoV-2 epitope Megapools (SARS-CoV-2 MPs) is used to study SARS-CoV-2 CD4 and CD8 specific T cell responses. The Megapool (MP) approach allows simultaneous testing of large number of epitopes. According to this approach large numbers of different epitopes are solubilized, pooled and re-lyophilized to avoid cell toxicity problems associated with high concentrations of DMSO typically encountered when single pre-solubilized epitopes are pooled. These MPs have been used for both CD4 and CD8 T cell epitope identification.

SARS-CoV-2表位Megapools（SARS-CoV-2 MP）用于研究SARS-CoV-2 CD 4和CD 8特异性T细胞应答。Megapool（MP）方法允许同时测试大量表位。根据该方法，将大量不同的表位溶解、合并并重新冻干，以避免与高浓度DMSO相关的细胞毒性问题，当合并单个预溶解的表位时通常会遇到高浓度DMSO。这些MP已用于CD 4和CD 8 T细胞表位鉴定。